Photo Credit: jack-sooksan
The following is a summary of “Bibliometric analysis of the usage of tenecteplase for stroke,” published in the November 2024 issue of Emergency Medicine by Bhasin et al.
Researchers conducted a retrospective study to assess the global trends in using tenecteplase with alteplase as a treatment for acute ischemic stroke.
They utilized the Web of Science database to collect data from articles published between 1999 and 2023 that included the keywords “Tenecteplase” and “Stroke.” They yielded 576 journal articles and analyzed the metadata, including country, institution, keywords, and publication date, for each article in the database related to tenecteplase use for stroke.
The results showed that the United States had the highest number of publications, with 260 articles (39.93%), followed by Australia with 101 articles (15.51%), and Canada and China, which tied for third place with 77 articles (11.83% each). The 3 most common keywords were tenecteplase (N = 324), alteplase (N = 284), and thrombolysis (N = 244). The leading institutions in publishing on tenecteplase as a treatment for stroke were the University of Melbourne and the University of Calgary. In 2023, the number of publications regarding the use of tenecteplase for stroke was at its highest, accounting for 24.3% of all papers on the subject.
Investigators concluded an increase in academic publications on tenecteplase for stroke in 2023 suggests a growing interest in its use, although it remains an off-label treatment in the US due to the lack of FDA approval.
Source: intjem.biomedcentral.com/articles/10.1186/s12245-024-00738-7
